Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

Laia Paré, David Paez, Juliana Salazar, Elisabeth Del Rio, Eduardo Tizzano, Eugenio Marcuello, Montserrat Baiget

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

AIMS To study the relationship between the toxicity associated with a 5-FU-based therapy and the presence of (i) the large intragenic rearrangements in the DPYD gene and (ii) the IVS14+1G>A mutation. METHODS We used the multiplex ligation-dependent probe amplification technique (MLPA) to study genomic DNA from 234 colorectal cancer patients treated with 5-FU-based chemotherapy. RESULTS We did not detect any deletion/duplication in the DPYD gene. The presence of the IVS14+1G>A mutation was also excluded. CONCLUSIONS Neither the large genomic rearrangements in the DPYD gene nor the IVS14+1G>A mutation play a significant role in the development of serious toxicity associated with a 5-FU containing regimen. © 2010 The British Pharmacological Society.
Original languageEnglish
Pages (from-to)268-272
JournalBritish Journal of Clinical Pharmacology
Volume70
Issue number2
DOIs
Publication statusPublished - 1 Aug 2010

Keywords

  • 5-FU
  • Dihydropyrimidine dehydrogenase gene
  • Multiplex ligation-dependent probe amplification (MLPA)

Fingerprint

Dive into the research topics of 'Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy'. Together they form a unique fingerprint.

Cite this